In vitro pharmacokinetics/pharmacodynamics of FL058 (a novel beta-lactamase inhibitor) combined with meropenem against carbapenemase-producing Enterobacterales
Frontiers in Pharmacology · 11.04.2024 · 15
DOI: 10.3389/fphar.2024.1282480 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.04.2024. Verfasst von Zhiwei Huang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
FL058 is a novel beta-lactamase inhibitor with a broad spectrum of activity and a favorable safety profile. The objective of this study was to evaluate pharmacokinetic/pharmacodynamic (PK/PD) relationships for the combination of FL058 and meropenem in an in vitro infection model.
Methods
By simulating human concentration-time profiles in the in vitro model, meropenem combined with FL058 when administered 1 g/0.5 g, 1 g/1 g, 2 g/1 g, and 2 g/2 g q8h by 3-h infusion achieved approximately 2- and 4-log10 kill to KPC/OXA-producing Klebsiella pneumoniae and Escherichia coli ; the combination therapy could not inhibit NDM-producing K. pneumoniae but could maintain NDM-producing E. coli around a baseline.
Results
The PK/PD indexes that best described the bacterial killing from baseline in log10 CFU/mL at 24 h were the percent time of free drug above the minimal inhibitory concentration (MIC) (%fT > MIC, MIC with FL058 at 4 mg/L) for meropenem and the percent time of free drug above 1 mg/L (%fT > 1 mg/L) for FL058. The targets for achieving a static effect and the 1- and 2-log10 kill were 74, 83, and 99 for %fT > MIC of meropenem and 40, 48, and 64 for %fT > 1 mg/L of FL058, respectively. The PK/PD index of %fT > 1 mg/L can provide a basis for evaluating clinical dosing regimens for FL058 combined with meropenem.
Conclusion
FL058 combined with meropenem might be a potential treatment for KPC- and/or OXA-48-producing Enterobacterales infection.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
- Phase I Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China.
- Qilu Pharmaceutical Co Ltd, Jinan, China.
Zitieren
APA
Huang, Z., Bian, X., Li, Y., Hu, J., Guo, B., Yang, X., Jin, Y., Zheng, S., Wang, X., Gao, C., Zhang, J., & Wu, X. (2024). In vitro pharmacokinetics/pharmacodynamics of FL058 (a novel beta-lactamase inhibitor) combined with meropenem against carbapenemase-producing Enterobacterales. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1282480
Vancouver
Huang Z, Bian X, Li Y, Hu J, Guo B, Yang X, et al. In vitro pharmacokinetics/pharmacodynamics of FL058 (a novel beta-lactamase inhibitor) combined with meropenem against carbapenemase-producing Enterobacterales. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1282480
BibTeX
@article{Huang2024,
author = {Huang, Zhiwei and Bian, Xingchen and Li, Yi and Hu, Jiali and Guo, Beining and Yang, Xinyi and Jin, Yi and Zheng, Shansong and Wang, Xinmei and Gao, Cong and Zhang, Jing and Wu, Xiaojie},
title = {In vitro pharmacokinetics/pharmacodynamics of FL058 (a novel beta-lactamase inhibitor) combined with meropenem against carbapenemase-producing Enterobacterales},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1282480}
}
EUVIMED